14.86
-0.34 (-2.24%)
| Penutupan Terdahulu | 15.20 |
| Buka | 14.75 |
| Jumlah Dagangan | 2,589,848 |
| Purata Dagangan (3B) | 2,386,831 |
| Modal Pasaran | 2,446,732,288 |
| Harga / Buku (P/B) | 2.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| EPS Cair (TTM) | -3.61 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.49% |
| Nisbah Semasa (MRQ) | 20.35 |
| Aliran Tunai Operasi (OCF TTM) | -319.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -176.84 M |
| Pulangan Atas Aset (ROA TTM) | -39.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Dyne Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.38 |
|
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.56% |
| % Dimiliki oleh Institusi | 110.24% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (HC Wainwright & Co., 236.47%) | Beli |
| Median | 39.00 (162.45%) | |
| Rendah | 16.00 (JP Morgan, 7.67%) | Pegang |
| Purata | 38.00 (155.72%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 17.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 03 Mar 2026 | 38.00 (155.72%) | Beli | 14.60 |
| 09 Dec 2025 | 38.00 (155.72%) | Beli | 18.44 | |
| HC Wainwright & Co. | 03 Mar 2026 | 50.00 (236.47%) | Beli | 14.60 |
| Morgan Stanley | 03 Mar 2026 | 47.00 (216.29%) | Beli | 14.60 |
| 09 Dec 2025 | 50.00 (236.47%) | Beli | 18.44 | |
| JP Morgan | 20 Jan 2026 | 16.00 (7.67%) | Pegang | 16.58 |
| Evercore ISI Group | 15 Dec 2025 | 36.00 (142.26%) | Beli | 19.59 |
| Stifel | 11 Dec 2025 | 39.00 (162.45%) | Beli | 19.42 |
| Oppenheimer | 10 Dec 2025 | 40.00 (169.18%) | Beli | 19.69 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
| 20 Jan 2026 | Pengumuman | Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 |
| 07 Jan 2026 | Pengumuman | Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 23 Dec 2025 | Pengumuman | Dyne Therapeutics Appoints Vikram Karnani to Board of Directors |
| 11 Dec 2025 | Pengumuman | Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares |
| 09 Dec 2025 | Pengumuman | Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |